Form 4: Conduit Pharmaceuticals Interim CFO James Bligh Reports Acquisition of 37,272 Shares
SEC Form 4 Filing
Interim CFO James Bligh reports acquiring 37,272 shares of Conduit Pharmaceuticals on June 11, 2024.
Summary
- On June 11, 2024, James Bligh, Interim CFO of Conduit Pharmaceuticals Inc. (CDT), acquired 37,272 shares of common stock.
- The shares were acquired directly and are fully vested as of the transaction date.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard reporting of stock acquisition by an officer. The acquisition itself could be seen as slightly positive, but the filing is purely informational.
Positives
- The acquisition of shares by a company officer can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of shares by an insider could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of the transaction where James Bligh acquired 37,272 shares of Conduit Pharmaceuticals. |
Keywords
Form 4, Beneficial Ownership, James Bligh, Conduit Pharmaceuticals, CDT, Interim CFO, Stock Acquisition, Shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.